HS-20093

Durvalumab demonstrated significant survival benefits as consolidation therapy after chemoradiation in limited-stage small cell lung cancer patients, establishing a potential new standard of care.

The FDA granted Breakthrough Therapy Designation to GSK's Jemperli (dostarlimab) for locally advanced dMMR/MSI-H rectal cancer.

The FDA granted Breakthrough Therapy Designation to GSK'227 for relapsed or refractory osteosarcoma after two prior lines of therapy.

HS-20093/GSK'227, a B7-H3-targeted ADC, has been granted FDA Breakthrough Therapy Designation for relapsed or refractory osteosarcoma after two prior lines of therapy.

Jiangsu Hansoh's HS-20093, a B7-H3-targeted ADC, has received Breakthrough Therapy Designation from China's NMPA for extensive-stage small cell lung cancer (ES-SCLC) following first-line treatment.